Generic placeholder image

Anti-Infective Agents


ISSN (Print): 2211-3525
ISSN (Online): 2211-3533

Review Article

'Mucormycosis': A Fungal Infection Threatening India During COVID-19' - A Review

Author(s): Sumel Ashique*

Volume 20, Issue 1, 2022

Published on: 22 December, 2021

Article ID: e301121198413 Pages: 7

DOI: 10.2174/2211352519666211130105217

Price: $65


During the second wave of Covid-19 in India, doctors recently reported a outbreak of cases involving a rare infection-called the “black fungus”-among recovering and recovered Covid-19 patients. The frequency of bacterial and fungal coinfections has been continuously rising. At the same time, invasive pulmonary aspergillosis is increasingly being recognized in association with nCOVID-19. Currently, India is suffering from a newly maiming disease associated with nCOVID-19 infected patients; at the time of the treatment, it can be developed into rhino-orbital mucormycosis. There are some approved antifungal therapies for treating this fungal infection. The background, risk factors, and associated reports about the infection are described in this review.

Keywords: Mucormycosis, nCOVID-19, source of infection, symptoms, reported cases, therapeutics.

Graphical Abstract
Available from: (Accessed May 23, 2021).
Available from: (Accessed May 23, 2021).
Fürbringer, P. Beobachtungen über lungenmycose beim menschen. Arch. Pathol. Anat. Physiol. Klin. Med., 1876, 66(3), 330-365.
Slavin, M.; van Hal, S.; Sorrell, T.C.; Lee, A.; Marriott, D.J.; Daveson, K.; Kennedy, K.; Hajkowicz, K.; Halliday, C.; Athan, E.; Bak, N.; Cheong, E.; Heath, C.H.; Orla Morrissey, C.; Kidd, S.; Beresford, R.; Blyth, C.; Korman, T.M.; Owen Robinson, J.; Meyer, W.; Chen, S.C. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clin. Microbiol. Infect., 2015, 21(5), 490.e1-490.e10.
[] [PMID: 25677259]
Chakrabarti, A.; Das, A.; Mandal, J.; Shivaprakash, M.R.; George, V.K.; Tarai, B.; Rao, P.; Panda, N.; Verma, S.C.; Sakhuja, V. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med. Mycol., 2006, 44(4), 335-342.
[] [PMID: 16772227]
Mehta, S.; Pandey, A. Rhino-orbital mucormycosis associated with COVID-19. Cureus, 2020, 12(9), e10726.
[PMID: 33145132]
Hibbett, D.S.; Binder, M.; Bischoff, J.F.; Blackwell, M.; Cannon, P.F.; Eriksson, O.E.; Huhndorf, S.; James, T.; Kirk, P.M.; Lücking, R.; Thorsten Lumbsch, H.; Lutzoni, F.; Matheny, P.B.; McLaughlin, D.J.; Powell, M.J.; Redhead, S.; Schoch, C.L.; Spatafora, J.W.; Stalpers, J.A.; Vilgalys, R.; Aime, M.C.; Aptroot, A.; Bauer, R.; Begerow, D.; Benny, G.L.; Castlebury, L.A.; Crous, P.W.; Dai, Y.C.; Gams, W.; Geiser, D.M.; Griffith, G.W.; Gueidan, C.; Hawksworth, D.L.; Hestmark, G.; Hosaka, K.; Humber, R.A.; Hyde, K.D.; Ironside, J.E.; Kõljalg, U.; Kurtzman, C.P.; Larsson, K.H.; Lichtwardt, R.; Longcore, J.; Miadlikowska, J.; Miller, A.; Moncalvo, J.M.; Mozley-Standridge, S.; Oberwinkler, F.; Parmasto, E.; Reeb, V.; Rogers, J.D.; Roux, C.; Ryvarden, L.; Sampaio, J.P.; Schüssler, A.; Sugiyama, J.; Thorn, R.G.; Tibell, L.; Untereiner, W.A.; Walker, C.; Wang, Z.; Weir, A.; Weiss, M.; White, M.M.; Winka, K.; Yao, Y.J.; Zhang, N. A higher-level phylogenetic classification of the Fungi. Mycol. Res., 2007, 111(Pt 5), 509-547.
[] [PMID: 17572334]
Ibrahim, A.S.; Spellberg, B.; Walsh, T.J.; Kontoyiannis, D.P. Pathogenesis of mucormycosis. Clin. Infect. Dis., 2012, 54(Suppl. 1), S16-S22.
[] [PMID: 22247441]
Spellberg, B.; Edwards, J., Jr; Ibrahim, A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev., 2005, 18(3), 556-569.
[] [PMID: 16020690]
Richardson, M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin. Microbiol. Infect., 2009, 15(Suppl. 5), 2-9.
[] [PMID: 19754749]
Roden, M.M.; Zaoutis, T.E.; Buchanan, W.L.; Knudsen, T.A.; Sarkisova, T.A.; Schaufele, R.L.; Sein, M.; Sein, T.; Chiou, C.C.; Chu, J.H.; Kontoyiannis, D.P.; Walsh, T.J. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin. Infect. Dis., 2005, 41(5), 634-653.
[] [PMID: 16080086]
Sugar, A.M. Agents of mucormycosis and related species. Prin. Pract. Infect. Dis., 2005, 2, 2973-2984.
Ibrahim, A.S.; Edwards, J.E.; Filler, S.G. Zygomycosis. In: Clinical mycology; Oxford. University. Press: New York, NY, 2003; pp. 241-251.
Clancy, C.J.; Schwartz, I.S.; Kula, B.; Nguyen, M.H. Bacterial superinfections among persons with coronavirus disease 2019: A comprehensive review of data from postmortem studies. In: Open forum infectious diseases; Oxford University Press, 2019.
Alanio, A.; Dellière, S.; Fodil, S.; Bretagne, S.; Mégarbane, B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir. Med., 2020, 8(6), e48-e49.
[] [PMID: 32445626]
Xia, Z.K.; Wang, W.L.; Yang, R.Y. Slowly progressive cutaneous, rhinofacial, and pulmonary mucormycosis caused by Mucor irregularis in an immunocompetent woman. Clin. Infect. Dis., 2013, 56(7), 993-995.
[] [PMID: 23243187]
Chowdhary, A.; Tarai, B.; Singh, A.; Sharma, A. Multidrug-resistant Candida auris infections in critically Ill coronavirus disease patients. Emerg. Infect. Dis., 2020, 26(11), 2694-2696.
[] [PMID: 32852265]
Ribes, J.A.; Vanover-Sams, C.L.; Baker, D.J. Zygomycetes in human disease. Clin. Microbiol. Rev., 2000, 13(2), 236-301.
[] [PMID: 10756000]
Petrikkos, G.; Skiada, A.; Lortholary, O.; Roilides, E.; Walsh, T.J.; Kontoyiannis, D.P. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis., 2012, 54(Suppl. 1), S23-S34.
[] [PMID: 22247442]
Youssef, O.H.; Stefanyszyn, M.A.; Bilyk, J.R. Odontogenic orbital cellulitis. Ophthal. Plastic. Reconst. Surgery, 2008, 24(1), 29-35.
[PMID: 18154930]
Sen, M.; Lahane, S.; Lahane, T.P.; Parekh, R.; Honavar, S.G. Mucor in a viral land: A tale of two pathogens. Indian J. Ophthalmol., 2021, 69(2), 244-252.
[] [PMID: 33463566]
Hindustan Times. Black fungus: Here is a list of states with highest number of mucormycosis cases. Available from: Accessed May 23, 2021
Healthline. Mucormycosis. Available from: (Accessed on May 23, 2021).
Cornely, O.A.; Alastruey-Izquierdo, A.; Arenz, D.; Chen, S.C.A.; Dannaoui, E.; Hochhegger, B.; Hoenigl, M.; Jensen, H.E.; Lagrou, K.; Lewis, R.E.; Mellinghoff, S.C.; Mer, M.; Pana, Z.D.; Seidel, D.; Sheppard, D.C.; Wahba, R.; Akova, M.; Alanio, A.; Al-Hatmi, A.M.S.; Arikan-Akdagli, S.; Badali, H.; Ben-Ami, R.; Bonifaz, A.; Bretagne, S.; Castagnola, E.; Chayakulkeeree, M.; Colombo, A.L.; Corzo-León, D.E.; Drgona, L.; Groll, A.H.; Guinea, J.; Heussel, C.P.; Ibrahim, A.S.; Kanj, S.S.; Klimko, N.; Lackner, M.; Lamoth, F.; Lanternier, F.; Lass-Floerl, C.; Lee, D.G.; Lehrnbecher, T.; Lmimouni, B.E.; Mares, M.; Maschmeyer, G.; Meis, J.F.; Meletiadis, J.; Morrissey, C.O.; Nucci, M.; Oladele, R.; Pagano, L.; Pasqualotto, A.; Patel, A.; Racil, Z.; Richardson, M.; Roilides, E.; Ruhnke, M.; Seyedmousavi, S.; Sidharthan, N.; Singh, N.; Sinko, J.; Skiada, A.; Slavin, M.; Soman, R.; Spellberg, B.; Steinbach, W.; Tan, B.H.; Ullmann, A.J.; Vehreschild, J.J.; Vehreschild, M.J.G.T.; Walsh, T.J.; White, P.L.; Wiederhold, N.P.; Zaoutis, T.; Chakrabarti, A. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis., 2019, 19(12), e405-e421.
[] [PMID: 31699664]
Reed, C.; Bryant, R.; Ibrahim, A.S.; Edwards, J., Jr; Filler, S.G.; Goldberg, R.; Spellberg, B. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin. Infect. Dis., 2008, 47(3), 364-371.
[] [PMID: 18558882]
Walsh, T.J.; Hiemenz, J.W.; Seibel, N.L.; Perfect, J.R.; Horwith, G.; Lee, L.; Silber, J.L.; DiNubile, M.J.; Reboli, A.; Bow, E.; Lister, J.; Anaissie, E.J. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin. Infect. Dis., 1998, 26(6), 1383-1396.
[] [PMID: 9636868]
Gleissner, B.; Schilling, A.; Anagnostopolous, I.; Siehl, I.; Thiel, E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk. Lymphoma, 2004, 45(7), 1351-1360.
[] [PMID: 15359632]
Rüping, M.J.; Heinz, W.J.; Kindo, A.J.; Rickerts, V.; Lass-Flörl, C.; Beisel, C.; Herbrecht, R.; Roth, Y.; Silling, G.; Ullmann, A.J.; Borchert, K.; Egerer, G.; Maertens, J.; Maschmeyer, G.; Simon, A.; Wattad, M.; Fischer, G.; Vehreschild, J.J.; Cornely, O.A. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J. Antimicrob. Chemother., 2010, 65(2), 296-302.
[] [PMID: 20008047]
Pagano, L.; Valentini, C.G.; Posteraro, B.; Girmenia, C.; Ossi, C.; Pan, A.; Candoni, A.; Nosari, A.; Riva, M.; Cattaneo, C.; Rossini, F.; Fianchi, L.; Caira, M.; Sanguinetti, M.; Gesu, G.P.; Lombardi, G.; Vianelli, N.; Stanzani, M.; Mirone, E.; Pinsi, G.; Facchetti, F.; Manca, N.; Savi, L.; Mettimano, M.; Selva, V.; Caserta, I.; Scarpellini, P.; Morace, G.; D’Arminio Monforte, A.; Grossi, P.; Giudici, D.; Tortorano, A.M.; Bonini, A.; Ricci, L.; Picardi, M.; Rossano, F.; Fanci, R.; Pecile, P.; Fumagalli, L.; Ferrari, L.; Capecchi, P.L.; Romano, C.; Busca, A.; Barbui, A.; Garzia, M.; Minniti, R.R.; Farina, G.; Montagna, M.T.; Bruno, F.; Morelli, O.; Chierichini, A.; Placanica, P.M.; Castagnola, E.; Bandettini, R.; Giordano, S.; Monastero, R.; Tosti, M.E.; Rossi, M.R.; Spedini, P.; Piane, R.; Nucci, M.; Pallavicini, F.; Bassetti, M.; Cristini, F.; LA, Sorda M.; Viviani, M. Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J. Chemometr., 2009, 21(3), 322-329.
[] [PMID: 19567354]
Singh, N.; Aguado, J.M.; Bonatti, H.; Forrest, G.; Gupta, K.L.; Safdar, N.; John, G.T.; Pursell, K.J.; Muñoz, P.; Patel, R.; Fortun, J.; Martin-Davila, P.; Philippe, B.; Philit, F.; Tabah, A.; Terzi, N.; Chatelet, V.; Kusne, S.; Clark, N.; Blumberg, E.; Julia, M.B.; Humar, A.; Houston, S.; Lass-Flörl, C.; Johnson, L.; Dubberke, E.R.; Barron, M.A.; Lortholary, O. Zygomycosis in solid organ transplant recipients: A prospective, matched case-control study to assess risks for disease and outcome. J. Infect. Dis., 2009, 200(6), 1002-1011.
[] [PMID: 19659439]
Groll, A.H.; Giri, N.; Petraitis, V.; Petraitiene, R.; Candelario, M.; Bacher, J.S.; Piscitelli, S.C.; Walsh, T.J. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis., 2000, 182(1), 274-282.
[] [PMID: 10882607]
Ibrahim, A.S.; Gebremariam, T.; Husseiny, M.I.; Stevens, D.A.; Fu, Y.; Edwards, J.E., Jr; Spellberg, B. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob. Agents Chemother., 2008, 52(4), 1573-1576.
[] [PMID: 18227182]
Cornely, O.A.; Maertens, J.; Bresnik, M.; Ebrahimi, R.; Ullmann, A.J.; Bouza, E.; Heussel, C.P.; Lortholary, O.; Rieger, C.; Boehme, A.; Aoun, M.; Horst, H.A.; Thiebaut, A.; Ruhnke, M.; Reichert, D.; Vianelli, N.; Krause, S.W.; Olavarria, E.; Herbrecht, R. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis., 2007, 44(10), 1289-1297.
[] [PMID: 17443465]
Sun, Q.N.; Fothergill, A.W.; McCarthy, D.I.; Rinaldi, M.G.; Graybill, J.R. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother., 2002, 46(5), 1581-1582.
[] [PMID: 11959605]
Pfaller, M.A.; Messer, S.A.; Hollis, R.J.; Jones, R.N. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother., 2002, 46(4), 1032-1037.
[] [PMID: 11897586]
Almyroudis, N.G.; Sutton, D.A.; Fothergill, A.W.; Rinaldi, M.G.; Kusne, S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob. Agents Chemother., 2007, 51(7), 2587-2590.
[] [PMID: 17452481]
Lass-Flörl, C.; Mayr, A.; Perkhofer, S.; Hinterberger, G.; Hausdorfer, J.; Speth, C.; Fille, M. Activities of antifungal agents against yeasts and filamentous fungi: Assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother., 2008, 52(10), 3637-3641.
[] [PMID: 18694949]
Arikan, S.; Sancak, B.; Alp, S.; Hascelik, G.; McNicholas, P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med. Mycol., 2008, 46(6), 567-573.
[] [PMID: 19180726]
Lekakis, L.J.; Lawson, A.; Prante, J.; Ribes, J.; Davis, G.J.; Monohan, G.; Baraboutis, I.G.; Skoutelis, A.T.; Howard, D.S. Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: Two cases and review of the literature. Biol. Blood Marrow Transplant., 2009, 15(8), 991-995.
[] [PMID: 19589489]
Mousset, S.; Bug, G.; Heinz, W.J.; Tintelnot, K.; Rickerts, V. Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation. Transpl. Infect. Dis., 2010, 12(3), 261-264.
[] [PMID: 19954497]
Schlemmer, F.; Lagrange-Xélot, M.; Lacroix, C.; de La Tour, R.; Socié, G.; Molina, J.M. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant., 2008, 42(8), 551-552.
[] [PMID: 18622416]
Spellberg, B.; Fu, Y.; Edwards, J.E., Jr.; Ibrahim, A.S. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother., 2005, 49(2), 830-832.
[] [PMID: 15673781]
Ibrahim, A.S.; Gebremariam, T.; Fu, Y.; Edwards, J.E., Jr; Spellberg, B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob. Agents Chemother., 2008, 52(4), 1556-1558.
[] [PMID: 18212099]
Boelaert, J.R.; Van Cutsem, J.; de Locht, M.; Schneider, Y.J.; Crichton, R.R. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int., 1994, 45(3), 667-671.
[] [PMID: 8196268]
Liu, M.; Spellberg, B.; Phan, Q.T.; Fu, Y.; Fu, Y.; Lee, A.S.; Edwards, J.E., Jr; Filler, S.G.; Ibrahim, A.S. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J. Clin. Invest., 2010, 120(6), 1914-1924.
[] [PMID: 20484814]
Cappellini, M.D. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract. Res. Clin. Haematol., 2005, 18(2), 289-298.
[] [PMID: 15737891]
Rodríguez, M.M.; Serena, C.; Mariné, M.; Pastor, F.J.; Guarro, J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob. Agents Chemother., 2008, 52(10), 3786-3788.
[] [PMID: 18694953]
Gil-Lamaignere, C. SimitFFsopoulou, M; Roilides, E; Maloukou, A; Winn, RM; Walsh, TJ Interferon-γ and granulocyte-macrophage colony-stimulating factors augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J. Infect. Dis., 2005, 191(7), 1180-1187.
[] [PMID: 15747255]
Gonzalez, C.E.; Couriel, D.R.; Walsh, T.J. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin. Infect. Dis., 1997, 24(2), 192-196.
[] [PMID: 9114146]
Greenberg, R.N.; Mullane, K.; van Burik, J.A.; Raad, I.; Abzug, M.J.; Anstead, G.; Herbrecht, R.; Langston, A.; Marr, K.A.; Schiller, G.; Schuster, M.; Wingard, J.R.; Gonzalez, C.E.; Revankar, S.G.; Corcoran, G.; Kryscio, R.J.; Hare, R. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother., 2006, 50(1), 126-133.
[] [PMID: 16377677]
Ben-Ami, R.; Lewis, R.E.; Tarrand, J.; Leventakos, K.; Kontoyiannis, D.P. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob. Agents Chemother., 2010, 54(1), 484-490.
[] [PMID: 19858263]
Busca, A.; Marmont, F.; Locatelli, F.; Limerutti, G.; Sorrentino, M.T.; Barbui, A.; Patrono, D.; Salizzoni, M.; David, E.; De Rosa, F. Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. Mycoses, 2010, 53(3), 275-278.
[] [PMID: 19302458]
Davies, B.W.; Smith, J.M.; Hink, E.M.; Durairaj, V.D. Increased incidence of rhino-orbital-cerebral mucormycosis after Colorado flooding. Ophthal. Plast. Reconstr. Surg., 2017, 33(3S)(Suppl. 1), S148-S151.
[] [PMID: 25794032]
NIH. Mucormycosis. Available from: (Accessed May 23, 2021).
Talmi, Y.P.; Goldschmied-Reouven, A.; Bakon, M.; Barshack, I.; Wolf, M.; Horowitz, Z.; Berkowicz, M.; Keller, N.; Kronenberg, J. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol. Head Neck Surg., 2002, 127(1), 22-31.
[] [PMID: 12161726]
Sivagnanam, S.; Sengupta, D.J.; Hoogestraat, D.; Jain, R.; Stednick, Z.; Fredricks, D.N.; Hendrie, P.; Whimbey, E.; Podczervinski, S.T.; Krantz, E.M.; Duchin, J.S.; Pergam, S.A. Seasonal clustering of sinopulmonary mucormycosis in patients with hematologic malignancies at a large comprehensive cancer center. Antimicrob. Resist. Infect. Control, 2017, 6(1), 123.
[] [PMID: 29225797]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy